ZEAL On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
text size: T | T
Back to Snapshot
Company Description

Contact Info

Smedeland 36

Glostrup

Copenhagen, 2600

Denmark

Phone: 45 88 77 36 00

Fax: 45 88 77 38 98

Zealand Pharma A/S, a biotech company, designs and develops novel peptide medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of adults with type 2 diabetes under the Lyxumia name. It also develops LixiLan, a single injection combination of lixisenatide and insulin glargine, which completed Phase III clinical trial for type 2 diabetes; and Elsiglutide, a GLP-2 peptide receptor agonist that is in Phase IIb clinical trial for the treatment of chemotherapy-induced diarrhea with colorectal cancer. In addition, the company develops Glucagon/GLP-1 dual agonist, which is in preclinical development to treat diabetes and/or obesity; a drug candidate that is in preclinical development for the treatment of cardio-metabolic diseases; and ZP4207, which is in Phase II clinical trial to treat hypoglycemia, as well as in Phase I clinical trial for hypoglycemia management in diabetes. Further, it develops ZP1848, a long-acting GLP-2 analogue that is in Phase II clinical trial for the treatment of short bowel syndrome; and ZP2929, a once-daily dual acting glucagon/GLP-1 receptor agonist, which is in Phase I clinical trial for patients with type 2 diabetes and/or obesity, as well as various therapeutic peptides in preclinical development. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.6x
Price/Book 24.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ZEALAND PHARMA A/S, please visit www.zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.